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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not dupilumab 
is a safe and effective treatment for patients with moderate-to-severe atopic dermatitis 
Study Design: Review of three randomized, double blind, placebo control trials between 2014-
2016. 
Data Sources: Three randomized, double blind, placebo controlled trials were found via 
EBSCOHost and PubMed. 
Outcomes Measured: In all three randomized controlled trials, outcomes measured includes the 
IGA score. Moderate-to-severe atopic dermatitis is a 3 or 4 on the IGA scale, respectively, while 
the goal was to get patients to a 0-1 on the IGA scale (indicating clear or almost clear disease 
state). 
Results: Three double-blind, randomized controlled clinical trials evaluated the use of 
dupilumab 300mg SQ weekly vs. placebo in patients with moderate-to-severe atopic dermatitis. 
The study done by Beck, et al. showed that 40% of patients improved on an IGA scale from 3-4 
to 0-1 compared to 7% in the control group. Simpson, et al. reported that 37% of patients 
improved to an IGA score of 0-1 compared to 10% in the control group. Thaçi, et al. had 33% of 
patients in that clinical trial with an IGA score of 0-1 compared to 2% in the control group. 
Conclusions: Review of these articles suggests that dupilumab is beneficial in treating patients 
with moderate-to-severe atopic dermatitis whom failed topical intervention. Long term use of 
dupilumab needs to be evaluated more thoroughly in long term trials. Concomitant use of 
dupilumab with topical glucocorticoids also prompts further evaluation in improved patient 
outcomes. 
Key Words: dupilumab, atopic dermatitis 
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Introduction 
 Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that is characterized 
by an up-regulation of type 2 immune responses, impaired skin barrier, and increased 
Staphylococcus aureus colonization.5 Patients with moderate-to-severe atopic dermatitis can 
experience intense pruritus, sleep deprivation due to the persistent pruritus, anxiety, and 
depression relating to their symptoms.5 These symptoms ultimately lead to a poor quality of life, 
which stems from the large amount of surface area skin lesions of moderate-to-severe atopic 
dermatitis can cover.5 Typically, patients will have exploited topical treatments and have gained 
little benefit due to the severity of the disease. Systemic treatment options have substantial side 
effects, such as cyclosporin, thus the need for a safe, long term systemic treatment.7 This paper 
evaluates three randomized controlled trials (RCTs) comparing the efficacy of dupilumab as 
monotherapy vs. placebo in treating moderate-to-severe atopic dermatitis. 
 Atopic dermatitis affects 3-10% of adults and up to 20% of children.7 Patients’ quality of 
life declines with moderate-to-severe disease.7 Adults with moderate-to-severe atopic dermatitis 
were surveyed via the 2013 National Health and Wellness Survey indicating that $27,164 is 
spent annually per patient in the treatment of atopic dermatitis and comorbidities.3 Comorbidities 
include hypertension, nasal allergies/hay fever, asthma, arthritis, and high cholesterol.3 This 
survey included emergency room visits, health care provider visit costs, and hospitalization 
costs.3 In adults with mild atopic dermatitis, $21,624 is spent annually, while adults without 
atopic dermatitis spend $14,619 annually.3 The survey indicates that adults with moderate-to-
severe atopic dermatitis see their provider 7-10 times annually, while they may see necessity for 
an emergency room visit or hospitalization once yearly.3 
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 Similarly to other atopic disorders, Th2 cytokines are prominent in atopic dermatitis, 
while Th1-mediated and Th22-mediated processes might have an association with the 
pathogenesis of atopic dermatitis.7 There have been clinical trials showing IL-4 and IL-13 are 
key Th2 cytokines that drive atopic diseases such as asthma and chronic sinusitis with nasal 
polyposis.7 When IL-4 and IL-13 are blocked, patients have shown significant improvements in 
their disease states.7 
Methods used to treat atopic dermatitis include topical glucocorticoids, systemic 
glucocorticoids, emollients, and calcineurin inhibitors such as tacrolimus.2 Cyclosporine is an 
approved systemic treatment for atopic dermatitis in some countries, but has been associated 
with a marked rebound effect after discontinuation of treatment along with systemic 
glucocorticoids.7 There is no systemic immunomodulator approved for the treatment of atopic 
dermatitis.7 
 The above treatments are currently used in the treatment of atopic dermatitis however, 
they don’t exhibit a lasting or significant effect on adults with moderate-to-severe atopic 
dermatitis.7 Due to the mechanism of action of dupilumab in blocking the signaling of IL-4 and 
IL-13 on asthma patients with moderate-to-severe disease and the similarity in patients with 
asthma and atopic dermatitis, it has shown effectiveness in moderate-to-severe atopic dermatitis.7 
Objective 
 The objective in this systematic review is to determine whether dupilumab is a safe and 
effective treatment for patients with moderate-to-severe atopic dermatitis. 
Methods 
 Criteria used in the collection of the studies includes adults 18 years or older with 
moderate-to-severe atopic dermatitis that isn’t adequately controlled with topical intervention. 
Viken, Atopic Dermatitis, 3 
 
The intervention was dupilumab 300mg subcutaneous injection weekly compared to placebo. 
The studies evaluated patients based on the IGA scale, a 5-point scale numbered 0-4. 0 indicated 
clear while 4 indicated severe disease. Types of studies included three randomized, double blind, 
placebo controlled clinical trials. 
 All articles were published in the English language in peer reviewed journals and chosen 
based on patient oriented evidence that matters (POEMs) and the relevance to the clinical 
question. Studies were found via PubMed and EBSCOHost utilizing key words such as 
“dupilumab” and “atopic dermatitis”. Inclusion criteria involved studies published within the last 
fifteen years that were randomized, double blind, placebo controlled clinical trials. Exclusion 
criteria included patients under 18 years of age, prior treatment with dupilumab, and severe 
comorbidities. 
 All studies presented dichotomous data, which enabled the calculation of the control 
event rate (CER), experimental event rate (EER), relative benefit increase (RBI), absolute benefit 
increase (ABI), and number needed to treat (NNT), relative risk increase (RRI), absolute risk 
increase (ARI), and number needed to harm (NNH). P values determined significance. 
 
Table 1: Demographics and Characteristics of Included Studies. 
  
 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Beck2 RCT 109 
Placebo: 54 
Dupilumab: 
55 
18+ Adults with 
moderate-to-
severe atopic 
dermatitis 
not 
adequately 
controlled by 
topical 
treatment. 
Less than 18 years of 
age, 
patients who had 
adequately controlled 
atopic dermatitis 
4 Dupilumab 
300mg SQ 
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Simpson5 RCT 671 
Placebo: 
224 
Dupilumab 
weekly: 
223 
18+ Moderate-to-
severe atopic 
dermatitis, 
IGA score of 
3 or 4, 
topical 
treatment 
providing 
inadequate 
control or 
was 
medically 
inadvisable, 
chronic 
atopic 
dermatitis 
for 3 years 
 
Less than 18 years of 
age, 
patients who didn’t 
qualify via the IGA 
score of length of time 
for dx of atopic 
dermatitis, 
patients who had 
adequately controlled 
atopic dermatitis 
6 Dupilumab 
300mg SQ 
Thaçi7 RCT 380 
Placebo: 61 
Dupilumab: 
63 
18+ Chronic 
atopic 
dermatitis 
for 3 years, 
IGA score of 
3, 
atopic 
dermatitis 
involvement 
of 10% or 
more of 
BSA, 
patients with 
a poor 
response to 
topical 
treatments 
 
Previous treatment 
with dupilumab, 
active acute or chronic 
infections, 
use of topical 
treatments for atopic 
dermatitis within 1 
week of baseline, 
systemic 
immunosuppressive or 
immunomodulating 
drugs within 4 weeks 
of baseline, 
significant 
comorbidities or 
laboratory 
abnormalities 
 
30 Dupilumab 
300mg SQ 
 
Outcomes Measured 
 Outcomes measured were in a static fashion with the Investigator’s Global Assessment 
(IGA) score. It is a 5 point scale ranging from 0-4. 0 indicates clear, 1 indicates almost clear, 2 
indicates mild disease, 3 indicates moderate disease, 4 indicates severe disease. The IGA score is 
based on consultation from a physician. The physician observes if the patient has erythema, 
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oozing, crusting, scaling, and other symptoms of atopic dermatitis and applies the IGA score 
accordingly. 
Results 
 All three randomized controlled trials were evaluating the effectiveness and safety of 
dupilumab vs. placebo on adults over the age of 18 with moderate-to-severe atopic dermatitis 
that was inadequately controlled by other interventions. Patients could never have previously 
used dupilumab, had comorbidities, or had adequately controlled atopic dermatitis to participate. 
Comparisons included dupilumab 300mg subcutaneously weekly vs. a placebo. Each study 
contained dichotomous data to calculate RBI, ABI, NNT, RRI, ARI, and NNH. There was no 
mention of clinical trial setting, nor compliance with intervention. 
 The study by Beck et al contained 109 patients diagnosed with moderate-to-severe atopic 
dermatitis that correlated with an IGA score of 3 or 4, respectively. Patients were randomized 
into a placebo group (n=54) and a dupilumab group (n=55). Patients in the placebo group 
received a subcutaneous injection weekly of placebo, while patients in the dupilumab group 
received a weekly subcutaneous injection of 300mg.2 All parties were kept blind throughout the 
12-week monotherapy trial.2 4 out of 109 patients withdrew for various reasons.2 1 patient 
withdrew from the dupilumab group due to an adverse reaction and 3 patients withdrew from the 
placebo group in the 12-week trial due to adverse reactions.2 After the trial, there were 54 
patients in the dupilumab group and 51 patients in the placebo group.2 
 The study by Beck at al utilized the IGA score to determine the severity of the patients’ 
disease before treatment, on day 29, and after the 12-week trial in both the placebo group and the 
dupilumab group. All patients in both groups had an IGA score of 3 or 4.2 At day 29, 2 (4%) 
patients in the placebo group had an IGA score of 0 or 1 while in the dupilumab group 10 (18%) 
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patients had an IGA score of 0 or 1.2 When the trial ended, 4 (7%) patients in the placebo group 
recorded an IGA score of 0 or 1 and in the dupilumab group, 22 (40%) recorded an IGA score of 
0 or 1.2 These results contain statistical significance (p value <0.001 and a CI of 95%) in patients 
whom achieved symptom reduction and an IGA score of 0 or 1.2 The NNT was calculated to be 
4, indicating that 4 patients needed to be treated in order to have a favorable outcome.2 ABI and 
RBI were also calculated (Table 2). 
 Simpson et al had a study containing 671 patients with 447 of those patients being 
evaluated in this systematic review. Patients must have a diagnosis of moderate-to-severe atopic 
dermatitis or an IGA score of 3-4, respectively.5 Patients were randomized into a placebo group 
(n=224) and a dupilumab group (n=223) where the placebo group received a subcutaneous 
injection weekly and the dupilumab group received a 300mg subcutaneous injection of 
dupilumab weekly.5 All parties were kept blind in the 16-week monotherapy trial.5 4 patients 
withdrew in the dupilumab group and 2 patients withdrew in the placebo group due to adverse 
reactions.5 At the end of the trial, 218 patients in the dupilumab group and 222 patients in the 
placebo group remained.5 
 The IGA score was used to determine the severity of the patients’ disease states in 
Simpson et al before the clinical trial began, and then again after 16 weeks of treatment. Initially, 
all patients had an IGA score or 3-4.5 After 16 weeks of dupilumab monotherapy, 83 (37%) 
patients reported an IGA score of 0 or 1 while the placebo group had 23 (10%) patients reported 
with an IGA score of 0 or 1.5 These results were statistically significant (p value <0.001) and the 
calculated NNT value was 4, indicating that in 4 people treated with dupilumab, 1 patient had a 
favorable outcome.5 ABI and RBI were also calculated (Table 2). 
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 The clinical trial by Thaçi et al utilized 380 patients diagnosed with moderate-to-severe 
atopic dermatitis that correlated with an IGA score of 3-4, respectively, 124 of which are 
evaluated in this systematic review. Patients were randomized into a placebo group (n=61) and a 
dupilumab group (n=63).7 Each group received a weekly subcutaneous injection with the 
dupilumab group receiving a 300mg injection of dupilumab instead of placebo.7 All parties were 
kept blind in the 16-week clinical trial.7 19 patients from the placebo group withdrew from the 
study and 11 patients from the dupilumab group withdrew from the study due to adverse 
reactions, lack of efficacy, lost to follow up, withdrawal by patient, or physician decision.7 At the 
end of the trial, 52 patients remained in the dupilumab group and 42 remained in the placebo 
group.7 
 Thaçi et al utilized the IGA score to determine the severity of patients’ atopic dermatitis 
before the trial began and after the 16-week trial concluded. All patients had an IGA score of 3-4 
indicating moderate-to-severe atopic dermatitis when starting the dupilumab or placebo 
monotherapy.7 After 16 weeks of monotherapy, 23 (33%) patients in the dupilumab group 
achieved an IGA score of 0 or 1, indicating clear or almost clear, while 1 (2%) patient in the 
placebo group achieved an IGA score or 0 or 1.7 These results were statistically significant (p 
value <0.0001).7 The confidence interval was 95% and ranged from 21.95-46.34 likely indicating 
a small sample size.7 NNT was calculated to be 4, meaning that for 4 people treated with 
dupilumab, 1 person has a favorable outcome.7 ARI and RRI were calculated (Table 2). 
 Adverse reactions were reported in all three clinical trials. Most commonly seen adverse 
reactions include: nasopharyngitis, headache, injection site reactions, exacerbations of atopic 
dermatitis, herpes simplex, conjunctivitis, and upper respiratory infection.2,5,7 Beck et al reported 
adverse reactions in 76% of patients in the dupilumab group and in 80% of patients in the  
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placebo group. Simpson et al reported adverse reactions in 69% of patients in the dupilumab 
group and 65% of patients in the placebo group. Thaçi et al reported 84% of patients in the 
dupilumab group and 80% of patients in the placebo group experienced adverse reactions. The 
RRI, ARI, and NNH were calculated as well (Table 3). The results of the calculations for adverse 
events signify that patients treated with dupilumab have a 5-6% higher risk of experiencing an 
adverse event when compared to placebo. The number needed to harm (NNH) indicates the 
number of patients that are treated with dupilumab to see one adverse reaction. 
Table 2: Analysis of outcomes in treatment with dupilumab. 
Name of Study Relative Benefit 
Increase (RBI) 
Absolute Benefit 
Increase (ABI) 
Number Needed to 
Treat (NNT) 
Beck et al 470% 33% 4 
Simpson et al 270% 27% 4 
Thaçi et al 155% 31% 4 
 
Table 3: Analysis of adverse reactions in treatment with dupilumab. 
Name of Study Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number Needed to 
Harm (NNH) 
Beck et al 5% 4% 25 
Simpson et al 6% 4% 25 
Thaçi et al 5% 4% 25 
 
Discussion 
 Atopic dermatitis is a chronic, systemic disease thought to be provoked mainly through 
Th2 mediated pathways.8 IL-4 and IL-13 are humoral mediated cytokines that contribute to the 
disease and are also the cytokines that dupilumab inhibits.8 Evidence also shows an increase in 
eosinophils, mast cells, and basophils in those with atopic dermatitis.8 Their mechanism of action 
is not fully understood however, they may play a role in skin protection.8 There is evidence that 
atopic dermatitis is associated with Th22, Th17, Th1, and epithelial dysfunction, all of which 
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contribute to disease severity and/or progression.8 Dupilumab works against atopic dermatitis by 
inhibiting IL-4 and IL-13 cytokines, effectively reducing the severity of the disease states. 
Dupilumab can cause patients to experience nasopharyngitis, headache, injection site reactions, 
exacerbations of atopic dermatitis, herpes simplex, conjunctivitis, and upper respiratory 
infection.2,5,7 Patients should report to their provider any history of eye problems, asthma, plans 
to become pregnant, or plans to receive a live vaccine prior to starting dupilumab.6 There are no 
black box warnings reported for this drug, nor studies indicating teratogenicity.6 
The articles only evaluated adults with atopic dermatitis, although children have a higher 
risk of developing atopic dermatitis. However, there are no biologic drugs approved for the 
treatment of atopic dermatitis. Systemic drugs used in children and adults to treat atopic 
dermatitis both have marked side effects and questionable safety for long term use, thus the need 
to evaluate dupilumab in adults. Dupilumab is FDA approved as of March 28, 2017.4 The FDA 
approved the use of dupilumab either as monotherapy or in conjunction with topical therapies in 
the treatment of atopic dermatitis.4 The expected annual cost of dupilumab will be $37,000, 
which is aligned with other biologic treatment costs for psoriasis.1 For insurance to cover costs of 
this drug, there will need to be extra steps for providers and patients.9 Patients will need to fail 
topical treatment options, have a prior authorization initiated by their health care provider, and 
must have a diagnosis of moderate-to-severe atopic dermatitis.9 
An obvious limitation to all three studies was the age of the sample size. Children were 
not evaluated in treatment of atopic dermatitis with dupilumab, only adults over the age of 18. 
There is evidence that most children with atopic dermatitis grow out of the disease by adulthood, 
but it is estimated that 25% or more of those children with atopic dermatitis will have persistent 
disease into adulthood. Other limitations to this study include the lack of consistent use of 
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glucocorticoids with dupilumab. This combination of drugs could prove useful in full 
management of atopic dermatitis. The lengths of the trials could be much longer, evaluating full 
treatment of patients in a 12 month timespan rather than a 3-4 month timespan. 
Conclusion 
 There is good evidence to suggest that dupilumab is a successful treatment for patients 
with moderate-to-severe atopic dermatitis whom have failed topical interventions. All three 
randomized controlled trials came to a similar conclusion that for every 4 patients treated with 
dupilumab, 1 patient will have the desired outcome. However, it is worth noting that this has 
potential to be further improved with concomitant use of topical glucocorticoids. Clinical trials 
with a combination of dupilumab and topical glucocorticoids should be conducted to evaluate the 
possibility of improved treatment outcomes with combination therapy. 
 It is also worth noting that dupilumab is an IL-4 and IL-13 antagonist from the Th2 
medicated pathways. As previously mentioned, Th22, Th17, and Th1 mediated pathways also 
have precedence in atopic dermatitis. Further evaluation of systemic drugs that affect these 
associated pathways should be prompted to compare treatment effectiveness with the different 
pathways. 
 Evaluation also needs to be done in patients under the age of 18 with moderate-to-severe 
atopic dermatitis whom failed topical interventions. There is evidence to suggest that pediatric-
based atopic dermatitis occurs with a different mechanism of action than adulthood atopic 
dermatitis. Therefore, this prompts evaluation on the disease state of childhood atopic dermatitis. 
Reviewing these RCTs has shown improved treatment options for patients with atopic dermatitis 
and provides an invitation for further research into the disease state itself as well as treatment 
options. 
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